Drugs / Semapimod
Trials 4
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT00741910 | Jul 2003 → Jun 2006 | Crohn disease | Ferring Pharmaceuticals | Completed | No outcome recorded |
| Phase 2 | NCT00740103 | Dec 2002 → Jul 2004 | Crohn disease | Ferring Pharmaceuticals | Completed | No outcome recorded |
| Phase 2 | NCT00739986 | Oct 2002 → Jun 2004 | Crohn disease | Ferring Pharmaceuticals | Completed | No outcome recorded |
| Phase 2 | NCT00038766 | Jun 2002 → Jun 2003 | Crohn disease | Ferring Pharmaceuticals | Terminated | No outcome recorded Stop: Enrollment |
Evidence & citations 8 cited values
Every value below carries the sentence it was read from. 5 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Semapimod | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00741910 ↗ |
| Known as | CPSI-2364 FREE BASE | ChEMBL registry synonym — accepted as the source's own label CHEMBL2107779 ↗ |
| Known as | Semapimod hydrochloride | ChEMBL registry synonym — accepted as the source's own label CHEMBL2107779 ↗ |
| Action | Inhibit | “an inhibitor of TNF-a synthesis” NCT00038766 ↗1“MAP kinase p38 alpha inhibitor” CHEMBL2107779 ↗ |
| Modality | Small molecule | “synthetic guanylhydrazone compound” NCT00038766 ↗ |
| Route | Intravenous | “Semapimod 60 mg IV x 5 days” NCT00038766 ↗ |
| Target | MAPK14 | “MAP kinase p38 alpha inhibitor” CHEMBL2107779 ↗ |
| Target | TNF | “an inhibitor of TNF-a synthesis” NCT00038766 ↗ |